Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as antidiabetic drugs, have been suggested to lower the incidence of HF-related admission and mortality in patients with DM [128]. This evidence concerns the gene SLC5A2 and hydrops fetalis.